Top-News
Biotechnologie USA

HedgePath Pharmaceuticals News

Aktie
WKN:  A1W4FM ISIN:  US42278K1025 US-Symbol:  INTI
0,118 $
+0,03 $
+34,09%
03.05.24 21:18:36
Handeln Depot/Watchlist
Aktienanzahl *
-
Marktkapitalisierung *
11,24 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website

HedgePath Pharmaceuticals News

19.12.23 - PR Newswire
Introducing Inhibitor Therapeutics, Inc. New Scientific Advisory Board
Introducing Inhibitor Therapeutics, Inc. New Scientific Advisory Board PR Newswire
13.12.23 - PR Newswire
Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University
Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University PR Newswire
19.08.19 - PR Newswire
HedgePath Pharmaceuticals Announces Name Change to INHIBITOR Therapeutics, Inc. and Ticker Symbol Change to "INTI" Effective August 20, 2019
HedgePath Pharmaceuticals Announces Name Change to INHIBITOR Therapeutics, Inc. and Ticker Symbol Change to "INTI" Effective August 20, 2019 New Corporate Brand ...
29.05.19 - PR Newswire
HedgePath Pharmaceuticals Announces Notice of Allowance with Additional Claims Governing the Use of SUBA®-Itraconazole for the Treatment of Lung Cancer
HedgePath Pharmaceuticals Announces Notice of Allowance with Additional Claims Governing the Use of SUBA®-Itraconazole for the Treatment of Lung Cancer New method of use ...
06.05.19 - PR Newswire
HedgePath Pharmaceuticals Announces Notice of Allowability of U.S. Patent Application Regarding Treatment of Prostate Cancer
HedgePath Pharmaceuticals Announces Notice of Allowability of U.S. Patent Application Regarding Treatment of Prostate Cancer Twenty new claims for use of itraconazole as a ...
15.04.19 - PR Newswire
W. Mark Watson Elected as Chairman of the Board of HedgePath Pharmaceuticals
W. Mark Watson Elected as Chairman of the Board of HedgePath Pharmaceuticals PR Newswire
07.03.19 - PR Newswire
HedgePath Pharmaceuticals Provides Corporate Update for the Fourth Quarter and Year End 2018
HedgePath Pharmaceuticals Provides Corporate Update for the Fourth Quarter and Year End 2018 Secured the potential for up to $5 million in new funding ($1.5 million of which ...
17.12.18 - PR Newswire
HedgePath Pharmaceuticals and Mayne Pharma Enter into Updated Collaboration and Funding Agreements
HedgePath Pharmaceuticals and Mayne Pharma Enter into Updated Collaboration and Funding Agreements HPPI to transfer SUBA-​Itraconazole BCCNS clinical program to Mayne ...
11.10.18 - PR Newswire
HedgePath Pharmaceuticals to Present at the 2018 BioFlorida Annual Conference
HedgePath Pharmaceuticals to Present at the 2018 BioFlorida Annual Conference BIOBUSINESS: Spotlight on Innovation Monday, October 15, 2018 at the Westin Fort Lauderdale, ...
09.10.18 - PR Newswire
HedgePath Pharmaceuticals' Pathway for Filing SUBA BCCNS NDA Clarified in Meeting with FDA
HedgePath Pharmaceuticals' Pathway for Filing SUBA BCCNS NDA Clarified in Meeting with FDA Key components of SUBA BCCNS NDA agreed to in FDA meeting minutes ...
06.08.18 - PR Newswire
HedgePath Pharmaceuticals Announces Positive FDA Feedback from FDA Type-C Meeting and Files Pre-NDA Meeting Request
HedgePath Pharmaceuticals Announces Positive FDA Feedback from FDA Type-C Meeting and Files Pre-NDA Meeting Request FDA has confirmed HPPI's clinical and regulatory ...
19.07.18 - PR Newswire
HedgePath Pharmaceuticals Granted Exclusive Option to License UCONN's Patented Chemical Analogues of Itraconazole
HedgePath Pharmaceuticals Granted Exclusive Option to License UCONN's Patented Chemical Analogues of Itraconazole Access to UCONN's technology could create the potential ...
09.07.18 - PR Newswire
HedgePath Pharmaceuticals Closes Second Tranche of Mayne Pharma Financing
HedgePath Pharmaceuticals Closes Second Tranche of Mayne Pharma Financing Additional $1.6 million in preferred stock and warrant funding to support SUBA BCCNS regulatory ...
05.06.18 - PR Newswire
HedgePath Pharmaceuticals Granted Meeting with FDA to Discuss SUBA BCCNS Trial Data and Regulatory Pathway
HedgePath Pharmaceuticals Granted Meeting with FDA to Discuss SUBA BCCNS Trial Data and Regulatory Pathway HPPI preparing patient dossiers for a July face-​to-face meeting ...
21.05.18 - PR Newswire
HedgePath Pharmaceuticals Announces Additional Expanded Patent Coverage
HedgePath Pharmaceuticals Announces Additional Expanded Patent Coverage HPPI's patent portfolio expands again with claims covering treatment of any non-​cancerous ...
14.05.18 - PR Newswire
HedgePath Pharmaceuticals Announces Expanded Patent Coverage
HedgePath Pharmaceuticals Announces Expanded Patent Coverage HPPI's patent portfolio expands with claims covering treatment of both hematologic and non-​hematologic ...
11.01.18 - PR Newswire
HedgePath Pharmaceuticals Secures New Funding from Mayne Pharma to Support BCCNS Clinical and Regulatory Approval Programs
HedgePath Pharmaceuticals Secures New Funding from Mayne Pharma to Support BCCNS Clinical and Regulatory Approval Programs HPPI receives three tranche preferred stock ...
30.10.17 - PR Newswire
HedgePath Pharmaceuticals Completes Enrollment for its Phase 2(b) Trial in BCCNS and Provides Trial Update
HedgePath Pharmaceuticals Completes Enrollment for its Phase 2(b) Trial in BCCNS and Provides Trial Update Positive outcomes continue to be observed in open label trial; ...
09.10.17 - PR Newswire
HedgePath Pharmaceuticals, Inc. Presentation Now Available for On-Demand Viewing
HedgePath Pharmaceuticals, Inc. Presentation Now Available for On-Demand Viewing PR Newswire
28.09.17 - PR Newswire
HedgePath Pharmaceuticals, Inc. to Webcast, Live, at VirtualInvestorConferences.com October 5
HedgePath Pharmaceuticals, Inc. to Webcast, Live, at VirtualInvestorConferences.com October 5 PR Newswire

Newssuche

Videos

08:55 Uhr -9,22%
Technical Trading: Rohöl Short Chance
Rohöl Short Typ: Turbo Open End WKN: VD4JF9 Hebel: 13 Laufzeit: OpenEnd Einstieg: Market ... Mehr »